Company in its Board Meeting has approved financial results for period ended 31st March,2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Concord Drugs reported strong revenue and profit growth for FY26. Standalone revenue surged 105% to Rs 7,585 lakhs from Rs 3,693 lakhs, while consolidated revenue grew 74% to Rs 7,874 lakhs from Rs 4,524 lakhs. Standalone PAT jumped 251% to Rs 104 lakhs from Rs 30 lakhs, and consolidated PAT rose 214% to Rs 106 lakhs from Rs 34 lakhs. EPS improved to Rs 0.93 (standalone) and Rs 0.95 (consolidated) from Rs 0.30 and Rs 0.34 respectively. However, operating cash flow turned sharply negative at Rs -677 lakhs (consolidated) versus Rs +372 lakhs in FY25, primarily due to a Rs 1,078 lakh increase in trade receivables. The auditors issued an Emphasis of Matter noting Rs 4.14 crore in long-outstanding receivables over 2 years with no provisioning, and balances subject to confirmation. During Q3 FY26, the company issued 31.75 lakh equity shares at Rs 36.30 per share on preferential basis.
While revenue and profit nearly doubled, the sharp turnaround to negative operating cash flow is a serious concern as it indicates revenue growth was not converted to actual cash collection. The auditors' emphasis on unprovided doubtful receivables raises questions about earnings quality and potential future write-offs. Shareholders should monitor cash collection trends and any provisioning impact on future profits.